Avient (AVNT) Q3 2025 earnings summary

Executive summary

• Q3 2025 sales were $806.5M–$807M, down 1%–1.1% year-over-year, with a 2% favorable FX impact; adjusted EPS was $0.70, up 4.5%–8% excluding FX, matching guidance.

• Net income for Q3 2025 was $32.6M–$32.8M, down 15.2% year-over-year, reflecting higher restructuring and impairment charges.

• Defense, healthcare, and telecom markets saw high single-digit growth, offsetting weak consumer sentiment and volatile trade policy impacts.

• Strong cash flow enabled $100M in debt repayment year-to-date, with $150M targeted for the year.

• Productivity initiatives and innovation in healthcare and defense supported margin expansion and cash generation.

Financial highlights

• Q3 2025 adjusted EBITDA was $132.9M, up from $130.0M; margin expanded to 16.5%, up 60 bps year-over-year.

• Adjusted EPS for Q3 was $0.70; September YTD adjusted EPS was $2.26, up 4.1% year-over-year.

• Q3 2025 operating income was $67.1M, down 13.1% year-over-year.

• Cash and cash equivalents at September 30, 2025 were $445.6M.

• Free cash flow expected at $190–$210M; capex forecast unchanged at $110M for the year.

Outlook and guidance

• Full-year 2025 adjusted EPS guidance is $2.77–$2.87 (+4% to +8% growth); adjusted EBITDA guidance is $540M–$550M.

• Q4 organic sales expected to be flat to down low-single digits, with potential for low single-digit growth depending on defense and energy project timing.

• Management expects sufficient liquidity for the next twelve months and foreseeable future.

• Additional productivity and cost actions planned if slow/no growth persists.

• Potential accelerators include improved consumer confidence and lower interest rates; decelerators include persistent inflation and possible US government shutdown.